Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
What it means for private plans For employer plan sponsors, the report frames GLP-1 receptor agonists as a category where unit-price reductions from generics may be offset by: Higher patient volumes as access expands [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php] New indications added to existing molecules [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php] New, longer-acting and oral GLP-1 entrants in development [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php] Patients tracking coverage developments can review the generic semaglutide tracker, the insurance coverage checker, and the FAQ for additional context on Canadian pricing and plan rules
Anekwe highlights that "some research shows GLP-1s may slow cognitive decline and have a role in neuroprotection." Addiction treatment
These occur most frequently during the initial titration phase, as dosage is increased from a starting level toward a therapeutic target
Erratic use may contribute to metabolic fluctuations
Phentermine is inexpensive and offers quick and short-term results, while Ozempic provides a slower but more sustainable and long-term approach
